ALLERGIC ASTHMA THERAPEUTICS MARKET ANALYSIS (2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
ALLERGIC ASTHMA THERAPEUTICS MARKET ANALYSIS
(2020-2027)

• Allergic Asthma Therapeutics Market, by Drug Type
  (Corticosteroids, Bronchodilators, Leukotriene
  modifiers, Immunotherapy, Biologics, and Others),
  by Route of Administration (Oral, Inhaled, and
  Others), and by Region (North America, Latin
  America, Europe, Asia Pacific, Middle East, and
  Africa) - Size, Share, Outlook, and Opportunity
  Analysis, 2020 - 2027

3

• There are lucrative opportunities for market
  players to enter potential markets in developed
  economies such as the U.S. and European
  countries, where the prevalence of chronic
  pulmonary diseases (COPD) is high.
• According to an analysis of the ISAAC
  (International Study for Asthma and Allergy in
  Childhood) in 2018, it is indicated that the
  prevalence of allergic asthma among adolescents
  and children is higher in developed countries.
  Among underprivileged communities of these
  countries, the rate of uncontrolled asthma is
  higher. On the other hand, according to secondary
  analysis of data generated by the World Health
  Organization (WHO) in 2018, symptoms of allergic
  asthma are less frequent in middle-income
  countries compared to high and low income
  countries

4

• The growing prevalence of respiratory diseases is
  expected to boost the growth of the global
  allergic asthma therapeutics market during the
  forecast period. For instance, according to the
  WHO, in 2018, around 235 million people were
  suffering from asthma and more than 200 million
  were suffering from chronic obstructive pulmonary
  disease (COPD).

5
Global Allergic Asthma Therapeutics Market -
Impact of Coronavirus (Covid-19) Pandemic

• The allergic asthma therapeutics market growth is
  hugely impacted by the sudden outbreak of
  COVID-19 all across the globe. Though the risk of
  asthma patients to be affected by COVID-19 is
  higher, authorities are taking utmost precaution
  to make the critical solutions (ventilators,
  inhalers) available to the patients. Supply for
  respiratory medications have not been affected
  due this pandemic.

6

• The comprehensive version of the report will
  include COVID-19s impact and the projected
  changes in the future outlook of the industry, by
  taking into the account the social, economic,
  political, and technological parameters.
• The allergic asthma therapeutics market is
  estimated to be valued at US 6,704.8
  million in 2020 and is expected to exhibit a CAGR
  of 2.9 during the forecast period (2020-2027).

7
Figure 1. Global Allergic Asthma Therapeutics
Market Share () Analysis, By Application, 2020
8

• The launch and approvals of novel drugs for
  asthma treatment are expected to boost the growth
  of the global allergic asthma therapeutics market
• Approvals and launch of novel drugs in the mark
  et are expected to propel the market growth and
  create lucrative growth opportunities for the
  market players during the forecast period.
• For instance, in June 2017, Teva Pharmaceuticals
  Industries Limited received U.S. FDA approval for
  its two products ArmonAirTM RespiClick and
  AirDuoTM Respiclick. These products are asthma
  inhalers for adolescent and adult patients
  suffering from asthma. ArmonAir RespiClick and
  AirDuo RespiClick are available to patients in
  the U.S. through prescription. The approved
  strength of AirDuo is 232/14 mcg, 113/14 mcg, and
  55/14 mcg, whereas, the approved strengths of
  ArmonAir is 232 mcg, 113, mcg, and 55 mcg
  directed as one inhalation twice daily.

9

• Furthermore, key players in the industry are
  strategically expanding to strengthen their
  position in the global market. For instance, in
  May 2019, ASLAN Pharmaceuticals, a
  Singapore-based clinical-stage immunology and
  oncology-focused biopharma company, amended its
  license agreement with CSL Limited (CSL). ASLANs
  aim behind this agreement was to have full global
  rights to develop, manufacture, and commercialize
  ASLAN004 in all indications. ASLAN004 is a
  fully human monoclonal antibody that helps in
  triggering the symptoms of allergic asthma such
  as coughing, wheezing, exacerbations of the
  disease, and shortness of breath.
• In October 2018, Sanofi and Regeneron
  Pharmaceuticals, Inc. announced the FDA approval
  of Dupixent (dupilumab) as an added maintenance
  therapy for patients suffering from
  moderate-to-severe asthma that are aged 12 years
  and above with an oral corticosteroid-dependent
  or eosinophilic phenotype asthma.

10
Global Allergic Asthma Therapeutics Market
Restraints

• However, the rising patent expiration of drugs is
  a major factor which is expected to hamper the
  growth of the allergic asthma therapeutics
  market. Also, lower awareness about novel drugs
  in rural areas of Asia Pacific and Africa are
  expected to result in slower adoption of allergic
  asthma therapeutics and hinder growth of the
  allergic asthma therapeutics market.
• Moreover, an increase in the use of generic drugs
  in such regions is also expected to restrict the
  growth of the allergic asthma therapeutics market
  during the forecast period.

11
(No Transcript)
12
Global Allergic Asthma Therapeutics Market
Regional Analysis

• North America accounted for majority of share in
  the global allergic asthma therapeutics market in
  2019 owing to the presence of major market
  players and approvals of novel drugs in the
  market For instance, in September 2018, Novartis
  AG received the US Food and Drug Administration
  (FDA) approval for its prefilled syringe
  formulation, Xolair (omalizumab). Xolair has been
  approved for 75 mg and 150 mg single dose for
  both chronic idiopathic urticaria (CIU) and
  allergic asthma.

13

• Moreover, diagnosis of this condition is critical
  for an effective treatment regimen. For instance,
  in September 2019, Genentech and Abionic entered
  a joint agreement to develop and provide quick
  point-of-care tests for asthma in the U.S.
  Genentech is funding the clinical and regulatory
  costs, whereas, Abionic has managed the
  pre-market procedure for the specific asthma
  panel.
• Furthermore, Asia Pacific is expected to witness
  significant growth in the global allergic asthma
  therapeutics market owing to initiatives taken by
  key players. Companies such as Aslan
  Pharmaceuticals, Kineta, and others are investing
  in research and development of novel drugs for
  allergic asthma.       

14

• Figure 2. Global Allergic Asthma Therapeutics
  Market Value (US Mn) Y-o-Y Growth (),
  2017-2027

15
Global Allergic Asthma Therapeutics Market -
Competitive Landscape

• Key players operating in the global allergic
  asthma therapeutics market are Aslan
  Pharmaceuticals Pte. Ltd., Baxalta Incorporated,
  Axikin Pharmaceuticals, Chiesi Farmaceutici SpA,
  CSL Limited, Circassia Pharmaceuticals Plc,
  Fountain Biopharma Inc., Hydra Biosciences,
  GlaxoSmithKline Plc, Infinity Pharmaceuticals,
  Mabtech Limited, Kineta, Marinomed Biotechnologie
  Gmb, NeoPharm Co., Mycenax Biotech Inc., Panacea
  Biotec Limited, and Oxagen Limited.

16

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/
  market-insight/allergic-asthma-therapeutics-market
  -4019

17
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

18
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

19

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/